



September 6, 2016

## Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- [Syndax Pharmaceuticals, Inc.](http://www.syndax.com) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in four upcoming investor conferences. The details for the four conferences are:

- 1 **The Citi 11<sup>th</sup> Annual Biotech Conference at the Mandarin Oriental Hotel in Boston, Massachusetts on September 8, 2016.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel titled "Developing Cancer Therapeutics in 2016" at 8:00 am EDT.
- 1 **The Morgan Stanley Global Healthcare Conference at the Grand Hyatt New York in New York City on September 12, 2016.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, and Michael A. Metzger, President and Chief Operating Officer of Syndax, will participate in an analyst led fireside chat at 10:30 am EDT.
- 1 **The Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference at the Lotte New York Palace Hotel in New York City on September 13, 2016.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 3:00 pm EDT.
- 1 **The 2<sup>nd</sup> Annual Ladenburg Thalmann 2016 Healthcare Conference at the Sofitel New York in New York City on September 27, 2016.** Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will make a presentation at 2:30 pm EDT.

A live webcast of these presentations can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the events will also be available for a limited time.

### About Syndax Pharmaceuticals, Inc.

Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to potentially enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is expected to begin clinical trials during the fourth quarter of 2016 and to be developed to treat a variety of cancers. For more information on Syndax, please visit [www.syndax.com](http://www.syndax.com).

### Syndax's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, the timing of the clinical development of SNDX-6352 and the potential use of SNDX-6352 to treat various cancer indications. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Investor and Media Contacts

Barbara Ryan  
bryan@syndax.com  
(646) 690-7639